| __timestamp | Amicus Therapeutics, Inc. | Viridian Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 47624000 | 293000 |
| Thursday, January 1, 2015 | 76943000 | 1002000 |
| Friday, January 1, 2016 | 104793000 | 888000 |
| Sunday, January 1, 2017 | 149310000 | 19623000 |
| Monday, January 1, 2018 | 270902000 | 30421000 |
| Tuesday, January 1, 2019 | 286378000 | 34794000 |
| Wednesday, January 1, 2020 | 308443000 | 28304000 |
| Friday, January 1, 2021 | 272049000 | 56886000 |
| Saturday, January 1, 2022 | 276677000 | 100894000 |
| Sunday, January 1, 2023 | 152381000 | 159765000 |
Data in motion
In the ever-evolving world of biotechnology, research and development (R&D) investments are crucial for driving innovation and breakthroughs. Over the past decade, Amicus Therapeutics, Inc. and Viridian Therapeutics, Inc. have demonstrated contrasting trajectories in their R&D spending.
Amicus Therapeutics has consistently increased its R&D investments, peaking in 2020 with a 547% increase from 2014. This commitment underscores their dedication to pioneering treatments and therapies. However, a notable dip in 2023 suggests a strategic shift or reallocation of resources.
Viridian Therapeutics, on the other hand, has shown a remarkable surge in R&D spending, especially from 2020 onwards, culminating in a 545% increase by 2023. This growth reflects their aggressive pursuit of innovation and expansion in the biotech sector.
These trends highlight the dynamic nature of R&D investments and their pivotal role in shaping the future of biotechnology.
Research and Development: Comparing Key Metrics for Eli Lilly and Company and Amicus Therapeutics, Inc.
Novo Nordisk A/S vs Viridian Therapeutics, Inc.: Strategic Focus on R&D Spending
Research and Development Expenses Breakdown: BioMarin Pharmaceutical Inc. vs Amicus Therapeutics, Inc.
R&D Insights: How Exelixis, Inc. and Amicus Therapeutics, Inc. Allocate Funds
Research and Development Investment: Blueprint Medicines Corporation vs Viridian Therapeutics, Inc.
R&D Spending Showdown: Alkermes plc vs Viridian Therapeutics, Inc.
Research and Development Investment: Apellis Pharmaceuticals, Inc. vs Amicus Therapeutics, Inc.
R&D Spending Showdown: Perrigo Company plc vs Amicus Therapeutics, Inc.
Research and Development Expenses Breakdown: Amicus Therapeutics, Inc. vs Geron Corporation
R&D Spending Showdown: Amicus Therapeutics, Inc. vs Galapagos NV
SG&A Efficiency Analysis: Comparing Amicus Therapeutics, Inc. and Viridian Therapeutics, Inc.